Diplomat Pharmacy, Inc. – Value Analysis (NYSE:DPLO) : April 19, 2017

Capitalcube gives Diplomat Pharmacy, Inc. a score of 53.

Our analysis is based on comparing Diplomat Pharmacy, Inc. with the following peers – Aceto Corporation, McKesson Corporation, AmerisourceBergen Corporation and Cardinal Health, Inc. (ACET-US, MCK-US, ABC-US and CAH-US).

Investment Outlook

Diplomat Pharmacy, Inc. has a fundamental score of 53 and has a relative valuation of NEUTRAL.

Fundamental Score

Access our research and ratings on Diplomat Pharmacy, Inc.

Company Overview

  • From a peer analysis angle, relative underperformance over the last year has improved more recently.
  • It trades at a lower Price/Book multiple (1.61) than its peer median (3.18).
  • The market expects faster earnings growth from DPLO-US than from its peers and also a turnaround in its current ROE.
  • DPLO-US has relatively low profit margins and median asset efficiency.
  • Changes in annual revenues (relative to peers) are better than the change in its earnings (relative to peers), implying the company is focused more on revenues.
  • DPLO-US‘s return on assets currently and over the past five years has trailed the peer median and suggests the company might be operationally challenged relative to its peers.
  • Company appears to give away relatively high gross margins to relatively high operating costs suggesting a differentiated product portfolio with low pre-tax margins relative to peers.
  • Compared with the peers chosen, DPLO-US has had faster revenue growth in prior years and a current P/E ratio that suggests faster growth in the future suggesting superior growth expectations.
  • The company’s capital investment program and to-date returns suggest that the company is likely making big bets on the future.
  • DPLO-US has the financial and operating capacity to borrow quickly.

Access our research and ratings on Diplomat Pharmacy, Inc.

Leverage & Liquidity

DPLO-US has the financial and operating capacity to borrow quickly.

  • With debt at a relatively low 14.99% of its enterprise value compared to an overall benchmark of 25% (Note: The peer median is currently 22.79%), and a well-cushioned interest coverage level of 6.60x, DPLO-US can probably borrow quickly. We classify the company as Quick & Able in terms of its capacity to raise additional debt.
  • All 4 peers for the company have an outstanding debt balance.

DPLO-US has maintained its Quick & Able profile from the prior year-end.

  • DPLO-US‘s interest coverage has declined 3.88 points from last year’s high and is now close to its four-year average interest coverage.
  • Though its interest coverage decreased to 6.60x from 10.48x (in 2015), its peer median remained relatively stable during this period at 11.37x.
  • Interest coverage fell 3.63 points relative to peers.
  • DPLO-US‘s debt-EV continues to trend upward but is still within one standard deviation below its four-year average debt-EV of 72.20%.
  • The increase in its debt-EV to 14.99% from 5.08% (in 2015) was also accompanied by an increase in its peer median during this period to 22.79% from 16.69%.
  • Relative to peers, debt-EV rose 3.80 percentage points.

Access the detailed analysis for Diplomat Pharmacy, Inc.

Key Liquidity Items

Company Debt/Enterprise Value (%) Current Ratio Interest Coverage (x) Cash Flow To Total Debt (%)
Aceto Corporation 39.29 2.21 5.16 18.38
McKesson Corporation 24.05 1.03 11.37 39.86
AmerisourceBergen Corporation 22.79 0.9 12.36 50.36
Cardinal Health, Inc. 20.65 1.1 12.35 41.88
Diplomat Pharmacy, Inc. 14.99 1.35 6.6 73
Peer Median 22.79 1.1 11.37 41.88
Best In Class 14.99 2.21 12.36 73

Looking for more metrics and analysis for Diplomat Pharmacy, Inc.?

Company Profile

Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. The firm stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It focuses on improving the lives of patients with complex chronic diseases. The company was founded by Dale Hagerman and Phil Hagerman in 1975 and is headquartered in Flint, MI.


The information presented in this report has been obtained from sources deemed to be reliable, but AnalytixInsight does not make any representation about the accuracy, completeness, or timeliness of this information. This report was produced by AnalytixInsight for informational purposes only and nothing contained herein should be construed as an offer to buy or sell or as a solicitation of an offer to buy or sell any security or derivative instrument. This report is current only as of the date that it was published and the opinions, estimates, ratings and other information may change without notice or publication. Past performance is no guarantee of future results. Prior to making an investment or other financial decision, please consult with your financial, legal and tax advisors. AnalytixInsight shall not be liable for any party’s use of this report. AnalytixInsight is not a broker-dealer and does not buy, sell, maintain a position, or make a market in any security referred to herein. One of the principal tenets for us at AnalytixInsight is that the best person to handle your finances is you. By your use of our services or by reading any our reports, you’re agreeing that you bear responsibility for your own investment research and investment decisions. You also agree that AnalytixInsight, its directors, its employees, and its agents will not be liable for any investment decision made or action taken by you and others based on news, information, opinion, or any other material generated by us and/or published through our services. For a complete copy of our disclaimer, please visit our website www.analytixinsight.com.